NCT05389423 2026-02-19
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
National Institutes of Health Clinical Center (CC)
AstraZeneca
Celgene
University of Washington
Shanghai Junshi Bioscience Co., Ltd.
Guangzhou Lupeng Pharmaceutical Company LTD.